Interim report 1 January – 31 March 2023

Strong organic growth in both business areas

"Strong organic growth of 12 percent this quarter reflects high demand
for our products and services. We are well-positioned for the recovery
that is now taking place in health care and is expected to continue for a long time to come."
Fredrik Dalborg, President and CEO

1 JANUARY – 31 MARCH 2023 (3 MONTHS)

• Net sales decreased by 5 percent to SEK 2,457m (2,579), partly driven by the fact that covid-19 related sales decreased to SEK 0m (510). Organic growth excluding covid-19 related turnover was 12 percent and acquired growth was 2 percent. 
• EBITA amounted to SEK 366m (435), corresponding to an EBITA-margin of 14.9 percent (16.9). EBITA includes a reversed contingent consideration amounting to 83m, adjusted for this the EBITA-margin amounts to 11.5 percent.
• Profit after tax amounted to  SEK 174m (225).
• Earnings per share amounted to SEK 1.43 (1.85). Earnings per share for the last 12 months amounted to SEK 3.54 (5.91).
• Cash flow from operating activities amounted to SEK 105m (332). 
• The equity ratio was 39 percent (38).
• Return on working capital (P/WC) amounted to 55 percent (61).